Ciprofloxacin, a new fluorinated quinolone, has been very useful in the treatment of Staphylococcus aureus infections, especially those caused by methicillin-resistant strains (MRSA) (10, 13, 15) . Ciprofloxacin-resistant methicillinsusceptible S. aureus (MSSA) strains and MRSA strains have been reported infrequently (3, 8) . In 1989, Schaefler reported that 5.2% of 2,833 S. aureus isolates, most of which were MRSA, from hospitals and nursing homes in New York City had high-level resistance to ciprofloxacin (12) .
The Ann Arbor Veterans Administration Medical Center, which includes an acute-care hospital and a chronic-care facility, has a high rate of colonization and infection with MRSA (1, 2) . In this study, we determined the susceptibility to ciprofloxacin of MSSA and MRSA strains isolated in 1989 and compared them with the susceptibility of isolates obtained from 1984 to 1985, when MRSA first occurred in our hospital.
Isolates from 1984 to 1985 were obtained from two sources: patients whose physicians had requested cultures through the clinical microbiology laboratory and employees who had nasal cultures obtained to determine colonization of personnel during an outbreak of MRSA infection.
The isolates from June to September 1989 were obtained from two sources: residents of the 100-bed extended-care facility attached to the acute-care hospital from whom isolates were obtained as part of an ongoing prospective study of colonization of nares, pharynx, perineum, rectum, and wounds with antibiotic-resistant organisms and patients in the acute-care hospital whose physicians had sent cultures to the clinical microbiology laboratory.
S. aureus was identified by the tube coagulase method from 1984 to 1985 and by the Accu-Staph latex agglutination method (Carr-Scarborough Microbiologicals, Inc., Decatur, Ga.) in 1989, using the tube coagulase method only for questionable reactions. Methicillin resistance was determined by growth after incubation for 24 h at 35°C on Mueller-Hinton agar containing 4% NaCl and 6 ,ug of oxacillin per ml (14) . Bacteriophage typing was done at the Michigan Department of Public Health laboratory by standard methods.
Organisms were screened for resistance to ciprofloxacin by dotting an inoculum of 104 CFU/ml in saline with a sterile * Corresponding author.
cotton applicator on Mueller-Hinton agar containing 4 ,ug of ciprofloxacin per ml. MICs of ciprofloxacin were determined on all ciprofloxacin-resistant strains and 50%o of randomly selected ciprofloxacin-susceptible strains by using MuellerHinton broth, as recommended by the National Committee for Clinical Laboratory Standards (9 ciprofloxacin resistance among S. aureus, especially MRSA, in both the acute-and chronic-care facilities associated with the Ann Arbor Veterans Administration Medical Center since the introduction of the fluoroquinolones into clinical use. Cases of ciprofloxacin resistance among staphylococci were reported while ciprofloxacin was still an investigational drug (3). Since its introduction into routine clinical use, there has been an increase in reports of ciprofloxacin-resistant staphylococci (4-8, 11, 12, 15) . Phage group analysis has been infrequently performed in other studies which looked at the development of ciprofloxacin resistance during clinical use. The finding in our study of multiple phage groups among the ciprofloxacin-resistant organisms suggests that the emergence of resistance occurred as separate events in multiple phage groups. With one phage group dominating, however, it appears that once resistance developed, person-to-person transmission within an environment favorable to spread resulted in widespread dissemination of resistant strains.
This study indicates that in the future, ciprofloxacin may be of limited utility in treating MRSA infections in facilities such as ours. 
